Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are conducting a large observational study called the China HeadAche Disorders Registry CHAIRS to better understand primary headaches and medication-overuse headaches MOH in patients aged 12 years and older. The study aims to collect detailed information including biomarkers, brain imaging, cognitive and genetic data, as well as social, demographic, medical, and treatment-related data. Long-term follow-up is planned to observe outcomes related to headache disorders over many years. Participants include those with various types of primary headaches such as migraine, tension-type headache, new daily persistent headache, and MOH. The study includes behavioral follow-up visits at multiple time points monthly for the first 18 months, then at 24 months, and annually thereafter. Some participants are observed during routine clinical use of treatments like Yangxue Qingnao Granules, Erenumab, and Eptinezumab, with treatment decisions made by their physicians and outcomes tracked over 12 weeks or longer. Throughout the study, participants undergo periodic assessments including MRI scans, cognitive tests like the Montreal Cognitive Assessment MoCA and Mini-Mental State Exam MMSE, and questionnaires evaluating headache impact, anxiety, depression, quality of life, sleep quality, and fatigue. Data on headache frequency, severity, medication use, and biological samples are collected. Follow-up can extend up to 10 years, allowing researchers to monitor long-term changes and outcomes related to headache disorders and treatments.
Actively Recruiting
Researchers are evaluating the safety and efficacy of TQH2722 injection combined with background therapy in people with seasonal allergic rhinitis. This multicenter, open-label, Phase II clinical trial aims to enroll 200 to 300 adults aged 18 to 75 who have seasonal allergic rhinitis with poor symptom control or dissatisfaction with symptom management during the previous pollen season. Participants will receive TQH2722 injection, a humanized monoclonal antibody targeting interleukin-4 receptor alpha, administered in treatment cycles lasting two weeks. The study is single-arm and open-label, meaning all participants receive the injection combined with their background treatment without placebo comparison. The treatment period is followed by assessments at baseline, 2 weeks, and 4 weeks to monitor nasal and ocular symptoms, quality of life, and laboratory tests. During the study, participants will be monitored for adverse events, serious adverse events, and changes in laboratory indicators up to 4 weeks after baseline. Nasal and ocular symptom scores will be recorded daily and retrospectively assessed at 2 and 4 weeks. Blood tests for eosinophil counts, immunoglobulin E levels, and lung function tests for those with asthma will be conducted up to 12 weeks. Participants must comply with study visits, symptom diaries, and safety evaluations throughout the trial, which continues until March 2027.
Actively Recruiting
This research aims to evaluate how previous induced termination of pregnancy affects complications and outcomes in later pregnancies. It is a prospective multicenter cohort study focused on reproductive health and abortion. The study seeks to understand the relationship between early pregnancy terminations and future pregnancy risks to improve knowledge in this area. Participants are women who have experienced an induced abortion within the first 12 weeks of pregnancy. The study observes these women over time without providing any experimental treatment, focusing on medical or surgical termination of pregnancy as the prior event. There are no intervention groups as this is an observational study. During the study, participants will be monitored for complications and adverse pregnancy outcomes. Researchers will collect data through follow-up investigations and evaluate pregnancy progress and health status. The primary outcome is adverse pregnancy outcomes reviewed by June 2028, with complications also tracked. Participation includes providing informed consent and cooperating with follow-ups over the study period.
Actively Recruiting
Researchers are evaluating the efficacy and safety of oral minocycline in patients who have experienced an acute spontaneous intracerebral hemorrhage within 48 hours of onset. This prospective, multicenter, randomized, double-blind, placebo-controlled Phase III trial aims to improve patient outcomes and explore the effects of minocycline on venous neuroinflammation in this condition. Participants will be randomly assigned to receive either minocycline or a matching placebo for 5 days alongside standard medical care. The minocycline group will take an initial dose of 200 mg immediately after randomization, followed by 100 mg every 12 hours for a total of 10 doses. Those with swallowing difficulties may receive the medication through a nasal feeding tube. The trial includes screening, treatment, and follow-up phases with visits scheduled at screening, 72 hours, 7 days, 90 days, and 180 days after randomization. During the study, participants will undergo assessments including neurological evaluations and imaging at specified time points. Researchers will measure outcomes such as the modified Rankin Scale score at 90 days, changes in neurological scores, inflammation markers, and stroke recurrence. Safety and efficacy will be monitored through these evaluations, with total participation lasting up to 180 days post-randomization.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of Yangxinshi tablets in patients with coronary heart disease combined with cardiac dysfunction. This study aims to determine if adding Yangxinshi tablets to standard treatment can reduce heart-related events, enhance exercise capacity, and improve quality of life and mental health. The trial includes 2708 patients and is a Phase 4 randomized controlled study sponsored by SPH Qingdao Growful Pharmaceutical Co., Ltd. Participants are randomly assigned to one of two groups one group receives conventional treatment plus Yangxinshi tablets 3 tablets taken orally three times a day, while the control group receives conventional treatment alone. Conventional treatment includes drugs such as aspirin, beta-blockers, statins, and others for symptom relief and improving heart outcomes. The treatment continues until a set number of heart-related events occur or the study ends. Throughout the study, participants undergo regular assessments including measurements of heart events, exercise tolerance, heart function tests, blood markers, and mental health questionnaires over an average of three years. Additional evaluations at 24 and 48 weeks include depression and anxiety scales, echocardiography, and exercise testing. The research team closely monitors safety, quality of life, and heart function throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of JX10, a thrombolytic drug, compared to a placebo in adults aged 18 to 90 who have experienced an Acute Ischemic Stroke AIS and present for care between 4.5 to 24 hours after stroke onset. The study aims to determine whether JX10 improves functional outcomes measured by the modified Rankin Scale and assess the risk of symptomatic intracranial hemorrhage associated with the treatment. The study has two parts. In Part 1, participants are randomly assigned to receive either JX10 at two different doses 1 mgkg or 3 mgkg or a placebo. In Part 2, participants receive either the optimal dose of JX10 selected from Part 1 or placebo. The study is double-blind and randomized to ensure unbiased results. Participants will be monitored for functional recovery over 90 days, with the primary outcome being the proportion of participants with no or minimal symptoms at 90 days post-treatment. Safety is tracked by recording incidence of symptomatic intracranial hemorrhage within 36 hours after randomization and adverse events throughout the study. Secondary measures include functional independence, ordinal Rankin scores, and incidence of major bleeding. The total duration of participation spans at least 90 days following treatment.
Actively Recruiting
Researchers are evaluating RC1416, a bispecific homodimer nanobody, in adults with severe uncontrolled asthma to assess its effectiveness and safety. This phase II study involves 195 participants diagnosed with moderate to severe asthma, aiming to improve lung function and reduce asthma symptoms according to the 2024 GINA guidelines. Participants will be randomly assigned to receive either RC1416 or a placebo by subcutaneous injection. Two different doses of RC1416 will be tested. The study will last 32 weeks, during which participants will be monitored regularly for treatment effects and safety. Throughout the study, participants will undergo lung function tests such as pre-bronchodilator forced expiratory volume in 1 second FEV1, peak expiratory flow, and forced vital capacity measurements. They will also complete questionnaires about asthma control and quality of life. Researchers will track asthma exacerbations, medication use, and adverse events. Blood samples will be collected for pharmacokinetics, pharmacodynamics, and anti-drug antibody analysis, ensuring comprehensive safety and efficacy monitoring for up to 32 weeks.
1-10 of 15
1